Direct comparison of the A to Z and PROVE IT trials: A second chance to gain a first impression

Circulation

Volumn 113, Issue 11, 2006, Pages 1382-1384

  Brown, B Greg ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Angioplasty; Atherosclerosis; Editorials; Lipoproteins

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; FLUINDOSTATIN; PLACEBO; PRAVASTATIN; SIMVASTATIN; TIROFIBAN; DRUG DERIVATIVE; HEPTANOIC ACID DERIVATIVE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PYRROLE DERIVATIVE; TYROSINE;

ACUTE HEART INFARCTION; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE MARKER; DRUG EFFECT; DRUG EFFICACY; DRUG ELUTING STENT; DYSLIPIDEMIA; EDITORIAL; HEART MUSCLE REVASCULARIZATION; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZATION; RISK FACTOR; RISK REDUCTION; STATISTICAL ANALYSIS; THROMBOGENESIS; TREATMENT DURATION; TREATMENT OUTCOME; AFRICA; ASIA; AUSTRALIA; BIOASSAY; BLOOD; CANADA; CASE MANAGEMENT; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; EPIDEMIOLOGY; EUROPE; HEART MUSCLE ISCHEMIA; METHODOLOGY; MULTICENTER STUDY; NEW ZEALAND; NOTE; RANDOMIZED CONTROLLED TRIAL; RISK; SOUTH AMERICA; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY; UNITED STATES; UTILIZATION REVIEW;

AFRICA; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASIA; AUSTRALIA; CANADA; CASE MANAGEMENT; CHOLESTEROL, LDL; CONFOUNDING FACTORS (EPIDEMIOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; ENDPOINT DETERMINATION; EUROPE; HEPTANOIC ACIDS; HUMANS; MULTICENTER STUDIES; MYOCARDIAL ISCHEMIA; NEW ZEALAND; PRAVASTATIN; PYRROLES; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; RISK; SIMVASTATIN; SOUTH AMERICA; STENTS; TREATMENT OUTCOME; TYROSINE; UNITED STATES;

EID: 33645822735     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.106.612374     Document Type: Editorial

References (14)

1. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292:1307-1316.
2. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
3. Wiviott SD, de Lemos JA, Cannon CP, Blazing M, Murphy SA, McCabe CH, Califf R, Braunwald E. A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. Circulation. 2006;113:1406-1414.
4. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711-1718.
5. Surreys PWJC, de Feyter P, Macaya C, Kokott N, Fuel J, Vrolix M, Branzi A, Bertolami MC, Jackson G, Strauss B, Meier B. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;287:3215-3222.
6. The T3A Investigators. Early effects of tissue plasminogen activator, added to conventional therapy, on the culprit coronary lesion in patients presenting with ischemic cardiac pain at rest. Circulation. 1993;87:38-52.
7. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, Szarek M, Libby P, Ganz P. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 2003;108:1560-1566.
8. Theroux P, Outmet H, McCans J, LaTour JG, Joly P, Levy G, Pelletier E, Waters DD. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 1988;319:1105-1111.
9. Mehta SR, Yusef S, Peters RJ. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527-533.
10. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278.
11. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437-2345.
12. Larosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
13. Brown BG, Zhao X-Q, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583-1592.
14. Whitney EJ, Krasuski RA, Personius BE, Michalek JE, Maranian AM, Kolusa MW, Monick E, Brown BG, Gotto AM. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med. 2005;142:95-104.